Equillium (EQ)
(Delayed Data from NSDQ)
$0.82 USD
+0.02 (2.65%)
Updated Sep 24, 2024 04:00 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Brokerage Reports
0 items in cart
Equillium, Inc. [EQ]
Reports for Purchase
Showing records 1 - 20 ( 42 total )
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
Possible October Itolizumab Option Exercise; 2Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
EQ101 Positive Top-Line Data in Alopecia Areata; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
EQUATOR Interim Enrollment Target Achieved; 1Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
Poster Presentation Elucidates Itolizumab Mechanism; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
Positive EQUALISE Type B Portion Data; 2023 Financials; Raising PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Updates Extend Celiac Disease Timeline; Lowering PT to $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
EQUALISE Data Presented; 3Q23 Financials; Lowering PT to $4.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
Share Repurchase Program Announced; 2Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
Itolizumab Agreement Yields Runway; Pipeline Progress; Lowering PT to $5.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
EQ102 Enters Phase 1 Clinical Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Data Presented at Immunology Conference; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
Positive EQUALISE Phase 2 Lupus Nephritis Interim Data; Raising PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
Metacrine Acquisition Lengthens Cash Runway; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
EQUALISE Data Release Imminent; 2Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
Baricitinib Alopecia Areata Approval Validates Clinical Path; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
Lupus Nephritis Data Imminent; 1Q22 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
Bioniz Acquisition Broadens Pipeline; 2021 Financials; Raising PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
Itolizumab Uncontrolled Asthma Phase 1b Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R